摘要
目的通过HPLC/MS平台探索血清代谢物对于乙肝相关性肝细胞癌(HCC)的诊断价值。方法选取126例就诊于天津市第三中心医院住院患者,包括27例乙肝DNA阴性乙肝肝炎患者、24例乙肝DNA阳性乙肝肝炎患者、24例乙肝肝硬化患者、27例乙肝相关性HCC行手术/射频治疗患者以及24例乙肝相关性HCC行介入治疗患者,另选取查体中心健康志愿者25例为对照组。将血清样本上机所得数据进行前处理,构建正交偏最小二乘判别分析(OPLS-DA)模型,基于乙肝组和正常对照组进行代谢物初筛。根据非参数检验的结果,最终筛选和鉴定特征代谢物。利用ROC分析这些特征代谢物的临床潜在应用价值。结果筛选并鉴定出25种特征代谢物,包括9种溶血性磷脂酰胆碱、2种脂肪酸、17α-雌二醇、二氢神经鞘氨醇、5-甲基胞苷、维生素K2、溶血磷脂酸、甘氨胆酸以及报道较少的8种物质。与正常对照组相比,22种代谢物在乙肝相关性HCC组中存在差异表达。与乙肝肝硬化组相比,4种代谢物在乙肝相关性HCC组中存在差异表达。与乙肝相关性HCC行手术/射频治疗组相比,10种代谢物在乙肝相关性HCC行介入治疗组中存在差异表达。从正常对照组到乙肝相关性HCC行介入治疗组,许多代谢物呈相同的变化趋势。结论基于LC/MS平台,本研究成功地构建疾病区分模型并筛选和鉴定出25种特征代谢物,这些代谢物对乙肝相关性HCC具有一定诊断和分期效能。有些特征代谢物呈连续性的变化预示着癌变的可能;有些代谢物对手术方式的选择也具有指导意义。
Objective To explore the diagnostic value of the serum metabolites identified by high-performance liquid chromatography-mass spectrometry (HPLC/MS) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods A total of 126 patients admitted to Tianjin Third Central Hospital were enrolled, including 27 patients with HBV-related hepatitis with negative viral DNA (DNA-N), 24 with HBV-related hepatitis with positive viral DNA, 24 with HBV-related liver cirrhosis, 27 with HBV-related HCC undergoing surgeries or radiofrequency ablation, and 24 with HBV-related HCC receiving interventional therapy, with 25 healthy volunteers as the normal control group. Serum samples were collected from all the subjects for HPLC/MS analysis, and the data were pretreated to establish an orthogonal partial least-squares discriminant analysis (OPLS-DA) model. The differential serum metabolites were preliminarily screened by comparisons between the HBV groups and the control group, and the characteristic metabolites were identified according to the results of non-parametric test. The potential clinical values of these characteristic metabolites were evaluated using receiver operator characteristic curve (ROC) analysis. Results A total of 25 characteristic metabolites were identified in the HBV-infected patients, including 9 lysophosphatidylcholines, 2 fatty acids, 17α-estradiol, sphinganine, 5-methylcytidine, vitamin K2, lysophosphatidic acid, glycocholic acid and 8 metabolites with few reports. The patients with HBV-related HCC showed 22 differential serum metabolites compared with the control group, 4 differential metabolites compared with patients with HBV-related liver cirrhosis; 10 differential metabolites were identified in patients with HBV-related HCC receiving interventional therapy compared with those receiving surgical resection or radiofrequency ablation. From the normal control group to HBV-related HCC treated by interventional therapy, many metabolites underwent variations following a similar pattern. Conclusions We identified 25 characteristic metabolites in patients with HBV-related HCC, and these metabolites may have potential clinical values in the diagnosis of HBV-related HCC. The continuous change of some of these metabolites may indicate the possibility of tumorigenesis, and some may also have indications for the choice of surgical approach.
作者
张磊
范志娟
康华
王宇凡
刘树业
单忠强
ZHANG Lei;FAN Zhijuan;KANG Hua;WANG Yufan;LIU Shuye;SHAN Zhongqiang(Chemical Engineering Institute, Tianjin University, Tianjin 300072 China;Clinical Laboratory Department of Tianjin Third Central Hospital, Tianjin Key Laboratory of Artificial Cell, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin 300170 China)
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2019年第1期49-56,共8页
Journal of Southern Medical University
基金
天津市自然科学基金-青年项目(16JCQNJC11600)
关键词
代谢组学
乙肝病毒
肝炎
肝硬化
肝癌
metabonomics
hepatitis B virus
hepatitis
liver cirrhosis
hepatocellular carcinoma